Mir-92 inhibitors and uses thereof
AssigneeMiragen Therapeutics, Inc.
InventorsChristina Marie Dalby, Corrie Lynn Gallant-Behm, Aimee Jackson, Kathryn Hutnick, Anita Seto
Life of this patent
Estimating the term…
Abstract
The present invention provides oligonucleotide inhibitors of miR-92 and methods of using said inhibitors for inhibiting the function and/or activity of miR-92 in a subject in need thereof. The present invention also provides methods for evaluating or monitoring the efficacy of a therapeutic for promoting wound healing and selecting a subject for treatment with a therapeutic that modulates miR-92 function and/or activity.
Claims58
A method for promoting wound healing in a subject comprising administering an oligonucleotide comprising a sequence that is at least partially complementary to miR-92, wherein the administration of the oligonucleotide reduces function or activity of miR-92, thereby promoting wound healing.
An oligonucleotide comprising a sequence selected from Table 2.
A method for evaluating or monitoring the efficacy of a therapeutic for modulating angiogenesis in a subject receiving the therapeutic comprising:
- a) measuring the expression of one or more genes listed in Table 3 in a sample from the subject;
- and
- b) comparing the expression of the one or more genes to a pre-determined reference level or level of the one or more genes in a control sample, wherein the comparison is indicative of the efficacy of the therapeutic.
A method for evaluating or monitoring the efficacy of a therapeutic for modulating wound healing in a subject receiving the therapeutic comprising:
- a) measuring the expression of one or more genes listed in Table 3 in a sample from the subject;
- and
- b) comparing the expression of the one or more genes to a pre-determined reference level or level of the one or more genes in a control sample, wherein the comparison is indicative of the efficacy of the therapeutic.
A method for evaluating an agent's ability to promote angiogenesis or wound healing comprising:
- a) measuring the expression of one or more genes listed in Table 3 in a cell contacted with the agent;
- and
- b) comparing the expression of the one or more genes to a pre-determined reference level or level of the one or more genes in a control sample, wherein the comparison is indicative of the agent's ability to promote angiogenesis or wound healing.
A method for selecting a subject for treatment with a therapeutic that modulates miR-92 function and/or activity comprising:
- a) measuring the expression of one or more genes listed in Table 3 in a sample from the subject, wherein the subject is treated with the therapeutic;
- and
- b) comparing the expression of the one or more genes to a pre-determined reference level or level of the one or more genes in a control sample, wherein the comparison is indicative of whether the subject should be selected for treatment with the therapeutic.
Dependencies are inferred from the claim text.